Forest's dexloxiglumide more effective than placebo

18 October 2001

Forest Laboratories' selective and reversible cholecystokinin receptorantagonist, dexloxiglumide, has been shown in a Phase II clinical trial to be superior to placebo in the treatment of constipation-predominant irritable bowel syndrome in females, according to an abstract submitted for the annual meeting of the American College of Gastroenterology, to be held in Las Vegas, USA, on October 22-24.

Results show that the response rate of IBS patients treated with dexloxiglumide was 40%, compared to 22% of those given placebo, and Forest says that it expects to begin a Phase III trial for the drug later this month.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight